Karyopharm Therapeutics (NASDAQ:KPTI) Earns Buy Rating from HC Wainwright

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $7.00 target price on the stock.

Several other research firms have also commented on KPTI. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Piper Sandler raised their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 5.9 %

KPTI opened at $0.63 on Wednesday. Karyopharm Therapeutics has a 52 week low of $0.58 and a 52 week high of $1.95. The company has a market capitalization of $79.90 million, a P/E ratio of -0.56 and a beta of 0.07. The stock’s fifty day moving average is $0.76 and its two-hundred day moving average is $0.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the previous year, the company earned ($0.30) earnings per share. Equities analysts anticipate that Karyopharm Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at $31,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Karyopharm Therapeutics in the second quarter valued at $143,000. Acadian Asset Management LLC purchased a new position in shares of Karyopharm Therapeutics during the second quarter worth about $167,000. Exchange Traded Concepts LLC lifted its holdings in shares of Karyopharm Therapeutics by 34.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after purchasing an additional 56,613 shares during the last quarter. Finally, FMR LLC increased its position in Karyopharm Therapeutics by 26.1% during the third quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after buying an additional 76,510 shares during the period. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).